Please select the option that best describes you:

In light of the TRIANGLE data at ASH, how are you now approaching a transplant-eligible patient with a new diagnosis of aggressive mantle cell lymphoma?   

Are you adding ibrutinib? Should we add ibrutinib to NORDIC? Still referring to transplant? 



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution